var data={"title":"Lutropin alfa (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lutropin alfa (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6489?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lutropin-alfa-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lutropin alfa (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122459\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Luveris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190577\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin;</li>\n      <li>\n        Ovulation Stimulator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190566\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Infertility:</b> Females (&ge;16 years to &le;60 years): SubQ: 75 units daily until adequate follicular development is noted (maximum dose: 75 units daily); maximum duration of treatment: 14 days, unless signs of imminent follicular development are present. Duration of stimulation may be extended in any one cycle up to 5 weeks (treatment should be individualized based on response to prior cycle). Administer concomitantly with follitropin alfa. Administer hCG one day after the last dose of lutropin alfa and follitropin alfa. Encourage patients to have daily intercourse beginning the day prior to hCG administration and until ovulation is apparent. If the ovaries are abnormally enlarged or if abdominal pain occurs, withhold hCG, discontinue lutropin alfa and follitropin alfa, and advise patient to avoid intercourse.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13812287\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13812288\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122480\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Subcutaneous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Luveris: 75 units [derived from or manufactured using Chinese hamster ovary cells]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Subcutaneous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Luveris: 450 units/0.72 mL [contains phenol, derived from or manufactured using Chinese hamster ovary cells; multidose pen]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122479\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190550\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer in the stomach or thigh; rotate injection sites. Do not shake solution; allow any bubbles to settle prior to administration. Contents of lutropin alfa vial may be mixed in the same syringe with follitropin alfa. Refer to manufacturer labeling for instructions on how to use lutropin alfa prefilled syringe.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190549\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infertility:</b> Stimulation of follicular development in infertile hypogonadotropic hypogonadal (HH) women with profound luteinizing hormone (LH) deficiency (&lt;1.2 units/L); to be used in combination with follitropin alfa</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190541\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 19%), pain (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian cyst (3% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (&le;16%), abdominal pain (7% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (18%), mastalgia (7% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (3% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian hyperstimulation (&le;9%), ovarian disease (3% to 6%), increased serum cholesterol (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% to 9%), constipation (4% to 7%), diarrhea (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (4%), increased serum AST (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Accidental injury, acne vulgaris, anaphylaxis, anxiety, back pain, breast hypertrophy, conjunctivitis, cough, dental caries, depression, dizziness, drowsiness, dyspnea, dysuria, ectopic pregnancy, edema, endometrium disease, enlargement of abdomen, fever, flu-like symptoms, genital edema, hemorrhage (in pregnancy), herpes simplex infection, hyperkinesia, hypersensitivity reaction, infection, insomnia, Klebsiella species, leg cramps, leg pain, leukorrhea, malaise, nail disease, nervousness, ovarian hyperstimulation syndrome, ovary enlargement, pelvic congestion syndrome, pelvic pain, pharyngitis, porphyria, premenstrual syndrome, rhinitis, shock, skeletal pain, skin rash, spontaneous abortion, thromboembolism, urination disorder (change in frequency), uterine disease, uterine spasm, vaginal hemorrhage, vaginitis, vasodilatation, vomiting, vulvovaginal candidiasis, weakness, xeroderma </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190553\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lutropin alfa or any component of the formulation; primary ovarian failure; uncontrolled thyroid or adrenal dysfunction; active, untreated tumors of the hypothalamus and pituitary gland; ovarian, uterine, or breast cancer; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement unrelated to polycystic ovarian disease and of undetermined origin; malformations of sexual organs incompatible with pregnancy; fibroid tumors of the uterus incompatible with pregnancy; pregnancy; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190539\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neoplasm: Benign and malignant neoplasms have been reported with multiple drug infertility treatment; causative association between gonadotropin therapy and increased risk of malignancy has not yet been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within 2 to 3 weeks; more common in women with polycystic ovarian syndrome. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian hyperstimulation syndrome: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: In association with and separate from ovarian hyperstimulation syndrome (OHSS), thromboembolic events have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Gonadotropins may increase the risk of an acute porphyric attack in patients with porphyria or a family history of porphyria; discontinuation of therapy may be necessary with onset or worsening of condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Not indicated for use in females &gt;60 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not indicated for use in females &lt;16 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting the treatment. Discontinuation of therapy is recommended if there is a high risk for multiple pregnancies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299623\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221384\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10239&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190554\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in women who are pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events have been observed in animal reproduction studies. Ectopic pregnancy, miscarriage, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after assisted reproductive techniques than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics). Lutropin alfa is used to stimulate follicular development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122460\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use in breastfeeding women is contraindicated per the manufacturer labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if lutropin alfa is present into breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190546\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prior to therapy: Baseline LH &lt;1.2 units/L, FSH &lt;5 units/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining alone or in combination with measurement of serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production. The indices most generally used are: rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature. Sonographic evidence of ovulation includes collapsed follicle, fluid in the cul-de-sac, ovarian stigmata, and secretory endometrium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for signs and symptoms of OHSS for at least 2 weeks following hCG administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190538\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lutropin alfa is a recombinant luteinizing hormone prepared using Chinese hamster cell ovaries. Administration leads to increased follicular estradiol secretion needed for follicle stimulating hormone induced follicular development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190552\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 10 to 14 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 56%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 21 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;5% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190555\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Luver-I.S. (MX);</li>\n      <li>Luveris (AE, AR, AT, AU, BE, BR, CH, CL, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, ID, IE, IL, IN, IT, JO, KR, KW, LB, LK, LT, LV, MT, MY, NL, NZ, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TR, TW, UY, VE, VN);</li>\n      <li>Lyuveris (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman, et al. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi:10.1016/S1701-2163(15)30417-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/22531097/pubmed\" target=\"_blank\" id=\"22531097\">22531097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility and Andrology Society (SOGC-CFAS) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/22416285/pubmed\" target=\"_blank\" id=\"22416285\">22416285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luveris (lutropin alfa) [product monograph]. Mississauga, Ontario, Canada: EMD Serono, A Division of EMD Inc, Canada; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lutropin-alfa-united-states-not-available-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10239 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F26122459\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F190577\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F190566\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13812287\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13812288\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F26122480\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F26122479\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F190550\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F190549\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F190541\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F190553\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F190539\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299623\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221384\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F190554\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26122460\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F190546\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F190538\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F190552\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F190555\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10239|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lutropin-alfa-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Lutropin alfa (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}